These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 19111385)
41. What is the future of prostate-specific antigen for the early detection of prostate cancer? Getzenberg R BJU Int; 2008 Jul; 102(2):157-8. PubMed ID: 18476972 [No Abstract] [Full Text] [Related]
42. Foreword: meeting the challenge of prostate cancer. Auvinen A; de Koning HJ; Coebergh JW Eur J Cancer; 2010 Nov; 46(17):3037-9. PubMed ID: 21047584 [TBL] [Abstract][Full Text] [Related]
43. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen. Fradet Y Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493 [TBL] [Abstract][Full Text] [Related]
44. New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era. Bickers B; Aukim-Hastie C Anticancer Res; 2009 Aug; 29(8):3289-98. PubMed ID: 19661347 [TBL] [Abstract][Full Text] [Related]
45. Early detection of prostate cancer. Loeb S; Cooperberg MR Urol Clin North Am; 2014 May; 41(2):xiii. PubMed ID: 24725496 [No Abstract] [Full Text] [Related]
46. Prostate specific antigen best practice statement: 2009 update. Greene KL; Albertsen PC; Babaian RJ; Carter HB; Gann PH; Han M; Kuban DA; Sartor AO; Stanford JL; Zietman A; Carroll P J Urol; 2009 Nov; 182(5):2232-41. PubMed ID: 19781717 [TBL] [Abstract][Full Text] [Related]
47. The Kallikrein Panel for prostate cancer screening: its economic impact. Voigt JD; Zappala SM; Vaughan ED; Wein AJ Prostate; 2014 Feb; 74(3):250-9. PubMed ID: 24166488 [TBL] [Abstract][Full Text] [Related]
52. PSA-based screening for localised prostate cancer. Uncertain benefits, potential adverse consequences, and many outstanding questions. Prescrire Int; 2009 Oct; 18(103):225. PubMed ID: 19882799 [No Abstract] [Full Text] [Related]
53. Screening for prostate cancer. Croswell J; Shin YR Am Fam Physician; 2013 Feb; 87(4):283-4. PubMed ID: 23418805 [No Abstract] [Full Text] [Related]
54. Editorial: Prostate cancer screening: perhaps a little patience is the answer. Jarrett TW Can J Urol; 2012 Oct; 19(5):6409. PubMed ID: 23040616 [No Abstract] [Full Text] [Related]
55. [New biomarkers and application of multivariate models for detection of prostate cancer]. Stephan C; Cammann H; Rittenhouse H; Lein M; Jentzmik F; Schrader M; Deger S; Miller K; Jung K Aktuelle Urol; 2009 Aug; 40(4):221-30. PubMed ID: 19634072 [TBL] [Abstract][Full Text] [Related]
56. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications. Aus G Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303 [No Abstract] [Full Text] [Related]
58. Human tissue kallikreins: the cancer biomarker family. Paliouras M; Borgono C; Diamandis EP Cancer Lett; 2007 Apr; 249(1):61-79. PubMed ID: 17275179 [TBL] [Abstract][Full Text] [Related]
59. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer. Boscolo-Berto R Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655 [No Abstract] [Full Text] [Related]
60. Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). Loeb S; Gashti SN; Catalona WJ Urol Oncol; 2009; 27(1):64-6. PubMed ID: 19111800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]